News Hub | News Direct

UC Asset Signed 2nd MoU to Speed Up Phase I of $4M Cannabis Deal

UC Asset LP

McapMediawire -- UC Asset LP (OTCQB: UCASU ) announced today that the company has signed second MOU on its recently announced deal of $4 million cannabis property transaction in the State of Oklahoma. Four weeks ago, UCASU entered into a MOU to acquire a 10,000 square foot cannabis cultivation property using $3 million non-cash payment, and to invest $1 million cash to build extra 5,000 square feet of facility at the same site. The new MOU details on what UCASU calls “Phase I” of the deal. In this Phase I, UC Asset will acquire 20% of ownership in the said property using non-cash payment of 500,000 preferred shares, and then will invest $1 million cash for the aforementioned expansion of the cultivation facility, while increasing UC Asset’s ownership to 50%. UC Asset will have the option to acquire the remained 50% ownership of the property by issuing 2 million preferred shares. “The updated plan of Phase I enables us to expediate the construction of the extra 5,000 square feet of cannabis cultivation facility, and therefore it will speed up the return from our investment,” claims Larry Wu, founder of UC Asset. “Now we are expecting to receive monthly payment after 3 months, in comparison to the previous plan under which we will only be paid after 6 months.” This expedition is a win-win solution for both parties, according to Wu. The State of Oklahoma will hold a special election in March to decide on marijuana legalization. It is projected that the result will be in favor of legalization. For this reason, it is very desirable to complete the said expansion of growing facility as soon as possible, possibly right after the legalization of recreational marijuana within the state. Most other terms and conditions remain the same, including the amount of monthly payment that UC Asset will receive, which will represent a 14.4% cash on cash annual return. It will still include protective terms for existing shareholders, so that the issuance of 500,000 preferred shares will not dilute the value of holdings by existing shareholders, particularly, it will not dilute dividends allocated to existing shareholders. This is possible since the preferred shares are not entitled to receive dividends unless converted into common shares, and the holder of preferred shares can only convert when revenue from the property has increased to a certain level. This 10,000 square foot cannabis property, according to UC Asset, is built to the state-of-art standard, with computerized and automatized environment control, and has the capacity to host full cycle cannabis production from creating clones/genetics to extracting cannabinoids. UC Asset has set a goal of $1 million gross profit for the year of 2023. And the speed-up of this deal will likely help UC Asset to reach that goal. About UC Asset LP UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com Disclaimer: This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed. For More Information Contact: IR@UCasset.com Contact Details Larry Wu IR@UCasset.com Company Website http://www.ucasset.com/

February 07, 2023 12:43 PM Eastern Standard Time

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

Context Therapeutics

Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial. Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer. The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added. Contact Details Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 07, 2023 12:21 PM Eastern Standard Time

Video

News Release

Avicanna completes first international export of cannabis seeds between Colombia and Spain

Avicanna Inc

Avicanna CEO Aras Azadian joined Proactive's Natalie Stoberman to discuss the completion of its first export of feminized cannabis seeds to Spain. Azadian said the company's majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS, sent its first commercial export of feminized cannabis seeds to Spain. The seeds are part of the Aureus portfolio of products which also includes proprietary genetics in the form of feminized seeds, cannabinoid extracts and purified compounds including CBD, CBG and THC. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:14 PM Eastern Standard Time

Video

News Release

Braxia Scientific signs non-binding letter of intent to sell company to Irwin Naturals

Braxia Scientific Corp.

Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company has agreed to a non-binding amended and restated letter of intent for a business combination with Irwin Naturals Inc. McIntyre told Proactive the transaction assembles an experienced management and scientific team in mental health treatment, research and development. The combined company will have 17 specialized mental health clinics across North America, an enhanced telehealth platform and access to critical treatments for millions of people across multiple states in the US. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:02 PM Eastern Standard Time

Video

News Release

Freedom Holdings Closes with MEDcann Industries, Inc.

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce that it has closed on the Definitive Agreement with MEDcann Industries as announced. The Closing took place on February 3, 2023, and the terms of the agreement have been consummated as follows: MedCann has purchased 40,000,000 Freedom restricted common shares for $50,000.00 and Brian Kistler has resigned all Officer/Director positions only to serve as an advisor for a period of 2 years to insure a smooth transition and John Vivian, CEO of MedCann has been appointed as the Chairman and CEO of Freedom, Robin Wright as C.F.O. and MEDcann (as the parent company) has assumed the debt and ongoing operational costs of Freedom. All financial disclosures are to be brought current. Brian Kistler, outgoing CEO, and Director stated: “This opportunity for the Company to take on the operations of MedCann Industries as a majority owned subsidiary will launch Freedom into the lucrative Cannabis industry for future development. I am pleased for the control of the Company to be taken over by the new management for a breath of new life for all of the shareholders.” John Vivian, incoming CEO and Chairman of the Board commented “I want to thank Brian for his confidence in our ability to take Freedom to new levels of shareholder value as we execute our plan of moving all operations into Freedom just as soon it is possible. We will update our shareholders as the plan unfolds.” “I am also pleased to have Ms. Wright join me on the Board of Directors and believe that our future is bright with their influence and expertise” concluded Vivian. BUSINESS DESCRIPTION: MEDcann Industries, Inc. - Medical Cannabis, Inc. is a developer and provider of next generation Cannabis driven products such as CBD & THC, cannabis 420 beverages, and Medical treatment solutions with Cultivation to help customers and patients increase their medical health and treatments to improve their illnesses and Cancers. Press Release Contact: John Vivian CEO MEDcann Industries, Inc 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details MEDcann Industries, Inc John Vivian +1 813-699-4098

February 07, 2023 09:00 AM Eastern Standard Time

InnerScope Hearing Technologies (OTC: INND) Featured in Official 2023 Super Bowl LVII Game Program

Innerscope Hearing Technologies, Inc.

2023 Official NFL Super Bowl LVII Game Program 1 Million Hard Copies 50 Million Unique Visitors - Digital Edition 500 Million Page Views - Digital Edition McapMediaWire -- InnerScope Hearing Technologies Inc. (OTC: INND ) ("InnerScope"), an emerging and disruptive leader in the Over-the-Counter (OTC) Hearing Aid space today announced its print ad campaign "Hearing Made Easy" is featured in the Official Super Bowl LVII (57) Game Program. Super Bowl LVII is a showdown between the AFC Champions, Philadelphia Eagles, and the NFC Champions, Kansas City Chiefs. The kickoff is this Sunday, February 12th, at 6:30 pm EST, with Chris Stapleton singing the National Anthem and international icon Rihanna taking center stage for Apple Music Super Bowl Halftime Show. The Official NFL Super Bowl LVII Commemorative Souvenir Game Program features InnerScope's print ad campaign strategically placed on page 229 opposite a full editorial that recaps the first four weeks of the Philadelphia Eagles regular season. The print ad campaign highlights a message of "Hearing Made Easy" – No Prescription Needed – No Medical Exam Needed with InnerScope's iHEAR and HearingAssist brand of Medical-Grade FDA-registered OTC rechargeable hearing aids starting at $499 a pair. The ad also includes a list of selected in-store and online major retailers where iHEAR and/or HearingAssist OTC hearing aids can be purchased, including Walmart Vision Centers, Walmart.com CVS.com, Bestbuy.com, RiteAid, RiteAid.com or directly from iHEARdirect.com or HearingAssist.com. NFL Super Bowl LVII Game Program will be made available to the fans during the game with exclusive distribution rights inside State Farm Stadium on Sunday, February 12, 2023. In addition, the publication will be made available for purchase nationwide at major newsstands, bookstores, hotels, mass and specialty stores, supermarkets, pharmacies, international airports, and online at NFLShop.com at a cover cost of $20 with a circulation of nearly 1,000,000 hard copies with 100% sell-thru and a pass along the value of approximately 5,000,000 (5 readers per copy). In addition to in-stadium and retail distribution, a robust digital component is included to enhance the visibility significantly: In the week preceding and following the game, the digital edition of the 2023 Official NFL Super Bowl LVII Game Program will be made available for free viewing on NFL.com. NFL.com expects to receive more than and experience approximately during this time. To view the digital edition of the 2023 Official NFL Super Bowl LVII Game Program, click the link here: Official Super Bowl 57 Game Program (hozinc.com). To View InnerScope's "Hearing Made Easy" print ad, type in the search box page 229. Also, in addition to the activation on NFL.com, All-Star Players and Media Personalities, with nearly 14 million combined opt-in followers, have agreed to share the publication over social media with their respective followers. FDA Ruling On OTC Hearing Aids Is A Game Changer For InnerScope An "FDA Ruling on OTC Hearing Aids went into effect on October 17, 2022, allowing millions of Americans with hearing loss to purchase hearing aids without a prescription, medical exam, or needing a professional to fit the hearing aids. But until the FDA ruling, getting hearing aids required a medical exam, prescription, and fitting done by an audiologist. In addition, the cost of professionally fitted hearing aids averages over $5,000 out-of-pocket costs for a pair because Medicare or private insurance plans don't typically cover the devices. However, FDA has established that OTC hearing aids are safe and effective for adults with perceived mild to moderate hearing loss and are regulated as medical devices by FDA. In addition, according to the National Institute on Deafness and Other Communication Disorders, as many as 30 million adults in the United States currently have some degree of hearing loss and would benefit from using hearing aids. The FDA ruling was a game changer for InnerScope since its iHEAR, and HearingAssist brands of OTC hearing aids have the same type of technology and features as hearing aids sold and fit by hearing healthcare professionals at an average saving of $3,000 to $4,000 per pair. Additionally, InnerScope's iHEAR and HearingAssist OTC hearing aids are designed for consumers with perceived mild to moderate hearing loss with many different models that feature Bluetooth App-Controlled and Full-Streaming for Hands-Free Phone Calling and Listening to Music and/or Podcasts. "We are proud to have our "Hearing Made Easy" ad campaign featured in the Official NFL Super Bowl LVII Commemorative Souvenir Game Program, said Matthew Moore, President and CEO of InnerScope Hearing Technologies. "Forbes has listed the Super Bowl as "the world's most valuable sporting event brand. The Official Super Bowl LVII Game Program is simply the most valuable, content-rich magazine in all sports. In addition, we believe InnerScope's iHEAR and HearingAssist OTC Hearing Aid brands associated with the Super Bowl brand and our "Hearing Made Easy" campaign print ad will provide awareness to millions of people that need hearing aids but, up until now, could never afford them." About InnerScope Hearing Technologies, Inc. (OTC: INND): InnerScope Hearing Technologies Inc. is a manufacturer and distributor of OTC Hearing Aids, Hearing Aid Accessories & Hearing Health-Related Products ("Hearing Products") dedicated to addressing the global demand for affordable hearing solutions. InnerScope's Hearing Products and its B2C and B2B business model break through the barriers that prevent access to effective and affordable hearing solutions. InnerScope's recent acquisition of iHear Medical Inc., a Direct-to-Consumer ("DTC") cloud-based hearing solution provider, gives the Company access to over 40 patents and an R&D facility. In addition, InnerScope has acquired HearingAssist, an established leader since 2008 in the DTC hearing aid market, with a customer base of over 400,000. These acquisitions, combined with a partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, will allow InnerScope to better position itself in the OTC hearing aid market by selling advanced Hearing Products through Walmart and many other major retailers and pharmacy chains. InnerScope's full line of Hearing Products is currently available through these multiple retail/wholesale distribution channels: Walmart Vision Centers, Walmart.com, Walmart Canada, CVS.com, RiteAid.com, BestBuy.com, Amazon.com, Fingerhut.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, Cardinal Health™ at-Home, Carewell.com FSAStore.com, HSAStore.com, WellDeservedHealth.com, Wakefern Food Corp. / ShopRite, SpartanNash / VG's Grocery / Family Fare / Martin's Super Markets and Topco Associates representing 1000's of stores. Coming Soon: More major retailers and pharmacy chains for InnerScope's in-store and online Hearing Products. For information related to InnerScope Hearing Technologies' latest hearing aids and related hearing products, please visit: http://iheardirect.com http://hearingassist.com For the most up-to-date information about InnerScope Hearing Technologies (OTC: INND), please visit and follow our official Twitter account @inndstock page: https://twitter.com/inndstock InnerScope Hyperlinks: HearingAssist HearingAssist - Walmart.com HearingAssist - CVS.com HearingAssist - RiteAid.com HearingAssist - BestBuy.com iHEAR iHEAR - CVS.com Acquisition of iHear Medical Inc. Acquisition of HearingAssist Safe Harbor This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, intended to be covered by the "safe harbor" created by those sections. Any statements that are not historical facts contained in this press release are also "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Such statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be canceled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or maintain contractual relationships with vendors and customers, competition, general economic conditions and other factors that are detailed in our periodic reports filed with the Securities and Exchange Commission ("SEC"). We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA, Securities Act, and Securities Exchange Act. Contact: InnerScope Hearing Technologies, Inc. Investor Relations ir@innd.com 833-788-0506 www.innd.com Investor Relations Agency Contact: Skyline Corporate Communications Group, LLC Lisa Gray, Senior Account Manager One Rockefeller Plaza, 11th Floor New York, NY 10020 Office: (646) 893-5835 Email: lisa@skylineccg.com Contact Details InnerScope Hearing Technologies, Inc. Investor Relations +1 833-788-0506 ir@innd.com Skyline Corporate Communications Group, LLC Lisa Gray, Senior Account Manager +1 646-893-5835 lisa@skylineccg.com Company Website http://www.innd.com/

February 07, 2023 08:30 AM Eastern Standard Time

Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research

Odyssey Group Intl Inc.

McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY ), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Based Partnership (CBP) with the David R. Metcalf Invisible Wounds Foundation, a non-profit organization that advances brain health care for active duty military and veterans by addressing traumatic brain injury (TBI) and suicide prevention among Naval Special Warfare and special operations forces. Between 2001 and 2021, over 30,000 active-duty personnel and veterans who served in the military after 9/11 died by suicide, compared to the 7,057 service members who died in combat during that same 20-year period. David Metcalf was a Navy SEAL, commissioned naval officer, and physician assistant. Following consecutive deployments and multiple TBIs, David was one of the many warriors who took his own life. Repetitive TBI is linked to Post-Traumatic Stress Disorder (PTSD), Post-Concussion Syndrome (PCS) and mental illness. Each of these conditions increase the rate of suicidal ideation and completion. A Community-Based Partnership (CBP) allows Odyssey Health’s scientific researchers across multiple disciplines to work side-by-side with the Metcalf Foundation’s community – many of whom have lived experience with TBI. The CBP assists in the development of Odyssey Health’s drug for treating TBI, specifically mild TBI (concussion). The CBP will include a needs assessment, clinical trial site planning, research intervention design, implementation, evaluation, and dissemination of community-level interventions. It is the CBP’s intent to enlist the support of the military community connected to The Metcalf Foundation with the research and scientists at Odyssey Health. This partnership will help make sure TBI interventions respond to the military community’s, particularly special operation forces, needs. The CEO of the David R. Metcalf Invisible Wounds Foundation is Shannon Finn Connell, Ph.D. She is a U.S. Navy SEAL parent and serves as an advisor to the Navy SEAL Foundation focused on initiatives for warriors transitioning from military service to civilian life. Shannon is a former executive with SYSCO, Shell Oil, and Procter & Gamble. She obtained her Ph.D. in organizational development, researching design thinking as a problem-solving method in global organizational change initiatives. “Our foundation is active in coordinating research groups, finding funding for care, and bringing awareness to the devastating epidemic of TBI and suicide in our Naval Special Warfare and special operations forces communities. We work with military members, both active and retired, and their families, who face their own challenges as TBI and suicide effects the mental fortitude of loved ones. We are excited by a potential treatment for acute concussion. Highly trained warriors, like David, are medically qualified to take care of themselves and team members in training and combat. The Metcalf Foundation believes the nasal device care and temperature stability of Odyssey Health’s drug will give it a greater chance of success and promote its use in this community of war fighters.” “Odyssey Health recognizes the need to have a partner associated with the US military that can not only give firsthand feedback about the effects of concussion but also help address logistics of treating the condition out in the field. Military medicine has different barriers to care than civilian medicine and we are excited to partner with the Metcalf Foundation to help us navigate and develop the first acute treatment for concussion,” commented Michael Redmond, Chief Executive Officer for Odyssey Health. “I am excited to be working with The Metcalf Foundation and Odyssey Health to develop an acute treatment for brain injury which is absolutely needed for our military men and women. Understanding the environment and logistics to care for our Special Operations Forces will be critical for the clinical success of Odyssey’s treatment. I will be assisting the Metcalf Foundation in establishing community feedback needed from our special forces operators to properly design and implement Odyssey Health’s clinical trials,” commented Tim Szymanski, Vice Admiral (Retired) and former Deputy Commander of the United States Special Operations Command. About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus on life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com We encourage our shareholders to visit our corporate social media accounts for updates: https://twitter.com/OdysseyHealth1 https://www.facebook.com/odysseyhealthinc https://www.linkedin.com/company/odysseyhealthinc https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q About ONP-002 ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, ONP-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that ONP-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, ONP-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Forward-Looking Statements This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete clinical trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions. Inquiries: Odyssey Health info@odysseyhealthinc.com David R. Metcalf Invisible Wounds Foundation info@davidrmetcalf.org Contact Details Odyssey Health Michael Redmond info@odysseyhealthinc.com

February 07, 2023 08:30 AM Eastern Standard Time

Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response

Precigen, Inc.

New hope may be on the horizon for sufferers of Recurrent Respiratory Papillomatosis, or RRP, a rare and debilitating disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas, that grow in the respiratory tract. Precigen, Inc. (Nasdaq: PGEN ) released complete data at a virtual R&D Day event on January 24, 2023 at 4:30 PM ET from a robust, open label Phase 1 trial of its investigational candidate PRGN-2012, an innovative gene-based immunotherapy designed to inhibit or prevent the growth of the dreaded papillomas in the hopes of reducing the number of surgeries. Clinical data presented showed a strong response in RRP patients with 50% of patients in complete response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2. All complete responders remained surgery-free post-treatment with a minimum 12-months of follow up. PRGN-2012 treatment at Dose Level 2 significantly reduced the need for surgeries in severe, aggressive RRP patients with the median number of surgeries in 12-month period being reduced from 6.5 pre-treatment to 0.5 post-treatment. The data also showed that PRGN-2012 was very well tolerated by patients, with no dose-limiting toxicities or treatment-related adverse events above Grade 2. A Phase 2 trial of PRGN-2012 in RRP is also underway and, depending on the results, it may qualify as a pivotal trial to facilitate the filing of a Biologics License Applications (BLA). It is approximately 85 percent enrolled to date. RRP affects both children and adults. Symptoms include a hoarse voice, difficulty sleeping and swallowing, chronic coughing, and breathing problems. In extreme cases, the disease can be fatal because the papillomas cause severe airway obstruction to the lungs and the lungs become flooded with fluids and infection. In a minority of patients RRP can malignantly transform into cancer. The company estimates indicate there are up to 16,000 active cases of RRP in the US and as many as 75,000 total worldwide, although there are believed to be thousands more undiagnosed cases. No therapeutic treatments are currently approved by the FDA. Company estimates suggest PRGN-2012 could have peak annual US sales of approximately $1 billion if approved. There is a high need for safe and effective therapeutic options for RRP. Currently, the only standard-of-care treatment for RRP is repeat surgeries to maintain voice and respiratory function. The sad reality is that many RRP patients require hundreds of surgeries over their lifetimes. The quality of life and economic burden of recurrent surgeries on patients, their families and physicians is very high. The surgeries are only effective at removing the built-up Human Papillomavirus Virus (HPV)-infected lesions in the respiratory tract, but they do not prevent further buildup. Patients often struggle to maintain consistent employment because of the frequent surgeries all while incurring costly medical bills. Moreover, frequent surgeries for RRP can worsen a patient’s condition overtime by potentially increasing the spread of the HPV virus and the likelihood of serious co-morbidities, including breathing issues and loss of vocal function. PRGN-2012 Seen as Promising, Potentially Less Costly Solution Lacking other treatments to potentially reduce the frequency of surgeries, some physicians have turned to off-label use of drugs approved for other indications, but without proven benefit for RRP patients. One such drug is cidofovir, a broad-spectrum antiviral drug from Gilead (GILD) and Pfizer (PFE) that was originally approved for treating CMV and HIV infection. It is prescribed by some physicians treating RRP, but it can cause liver toxicity and patients typically rebound after withdrawal, making it –at best-- a short-term solution. Another is Avastin® from Roche Holdings (RHHBY), an antiangiogenic drug in wide use as a cancer therapy. Avastin has been shown to temporarily slowdown papilloma growth in some RRP patients. However, it can cause severe side effects and cannot activate specific T cells needed to eliminate HPV infected cells responsible for papilloma growth in RRP. Currently, the most promising solution appears to be Precigen’s PRGN-2012 gene therapy which works by activating anti-HPV T cells to induce immunity against HPV subtypes 6 and 11, which are responsible for RRP. If the on-going Phase 2 trial shows positive results, PRGN-2012 could be on its way to becoming a standard of care for reducing the burden of surgeries, lowering care costs and improving the quality of life of RRP patients. In a study conducted on behalf of Wells Fargo, 10 ear, nose, throat physicians who treat RRP responded very favorably to the use of a drug with a PRGN-2012-target profile of safety and efficacy. Precigen’s clinical-stage pipeline also includes Phase 1 and Phase 2 programs in immuno-oncology and infectious and autoimmune diseases. PRGN-2012 is Precigen’s innovative therapeutic vaccine for RRP patients. Analyst price targets for PGEN as of August 2022 range from $6 to $14, with buy or market outperform ratings issued by Stifel, JMP Securities, Cantor Fitzgerald, and H.C. Wainwright. Click Here for Additional Information About Precigen (PGEN) This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Featured photo By Gorodenkoff on Shutterstock Precigen: Advancing Medicine with Precision ™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders,and infectious diseases. Our technologiesenable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Contact Details Steven M. Harasym sharasym@precigen.com Company Website https://precigen.com/

February 07, 2023 08:00 AM Eastern Standard Time

Image

Tulane University Announces First Transformative Agreement with Elsevier

Elsevier

Elsevier, a global leader in research publishing and information analytics, and Tulane University, a leading research institution in the Gulf Coast of the United States, are pleased to announce the institution’s new transformative agreement for reading and publishing. The Transformative Agreement will continue to provide access to the same extensive portfolio of ScienceDirect journals that enhance the learning and research experience for the Tulane community while now also supporting all researchers in publishing their research Open Access at no extra cost to the author. Through this agreement, Tulane faculty, students, and staff will have access to Elsevier's extensive library of scholarly journals and eBooks on ScienceDirect. This will give Tulane researchers the tools they need to stay at the forefront of their fields and make and share essential discoveries. In addition to providing access to these resources, the agreement also includes support for open access publishing, allowing Tulane researchers to share their work more broadly and collaborate with colleagues worldwide. “We are very pleased to have worked in partnership with Elsevier to expand the scope of our agreement to now include Open Access publishing options for our scientific and medical communities,” said Tulane University Interim Dean of Libraries Andy Corrigan. “This new arrangement accomplishes three important goals. It supports public access to grant funded research, addresses cost sustainability within our library budget, and it increases the university’s overall return on investment in supporting the acquisition of high-quality library resources such as important ScienceDirect journals that are relied upon by our students, faculty and researchers.” “Elsevier is committed to supporting Tulane’s open access objectives" said James Tonna, Vice President, Elsevier. "We are thrilled to be able to provide Tulane researchers with the tools they need to make important discoveries and contribute to advancing knowledge." --- About Tulane University Tulane University is a private, independent research university in New Orleans, Louisiana. Founded in 1834, Tulane is one of the oldest and most prestigious universities in the southern United States, with a strong tradition of research and teaching in the sciences, engineering, business, law, and the liberal arts. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including “ The Lancet ” and “ Cell ”; our 40,000 e-Book titles; and our iconic reference works, such as “Gray’s Anatomy.” With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Andrew Davis Andrew.davis@elsevier.com Company Website https://www.elsevier.com/

February 07, 2023 08:00 AM Eastern Standard Time

Healthcare

UC Asset Signed 2nd MoU to Speed Up Phase I of $4M Cannabis Deal

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

Avicanna completes first international export of cannabis seeds between Colombia and Spain

Braxia Scientific signs non-binding letter of intent to sell company to Irwin Naturals

Freedom Holdings Closes with MEDcann Industries, Inc.

InnerScope Hearing Technologies (OTC: INND) Featured in Official 2023 Super Bowl LVII Game Program

Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research

Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response

Tulane University Announces First Transformative Agreement with Elsevier